Loading...
XTAI6541
Market cap306mUSD
Dec 23, Last price  
61.10TWD
1D
0.49%
1Q
-10.28%
Jan 2017
-60.11%
IPO
-42.07%
Name

Tanvex BioPharma Inc

Chart & Performance

D1W1MN
XTAI:6541 chart
P/E
—
P/S
163.24
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
10.27%
Rev. gr., 5y
%
Revenues
61m
+174.11%
0000000300,0005,406,00022,404,00061,411,000
Net income
-2.14b
L+30.22%
-299,032,000-472,485,000-835,255,000-1,244,446,000-1,409,800,000-1,893,862,000-2,274,226,000-2,104,236,000-1,543,211,000-1,641,130,000-2,137,101,000
CFO
-1.43b
L+7.49%
-239,857,000-434,173,000-684,195,000-833,426,000-1,212,016,000-1,605,885,000-1,898,660,000-1,787,625,000-1,387,021,000-1,333,847,000-1,433,809,000
Earnings
Mar 12, 2025

Profile

Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar in Taiwan and the United States. The company focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Its products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
URL
http://www.tanvex.com/
IPO date
Aug 13, 2015
Employees
Domiciled in
KY
Incorporated in
KY

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
61,411
174.11%
22,404
314.43%
5,406
1,702.00%
Cost of revenue
2,162,161
1,627,921
1,604,590
Unusual Expense (Income)
NOPBT
(2,100,750)
(1,605,517)
(1,599,184)
NOPBT Margin
Operating Taxes
428
23
22
Tax Rate
NOPAT
(2,101,178)
(1,605,540)
(1,599,206)
Net income
(2,137,101)
30.22%
(1,641,130)
6.35%
(1,543,211)
-26.66%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,207,210
7,235
1,690,429
BB yield
-14.25%
-0.06%
-8.68%
Debt
Debt current
163,448
124,654
88,746
Long-term debt
3,300,114
3,553,818
3,429,306
Deferred revenue
10,230
Other long-term liabilities
10,469
Net debt
2,881,330
2,688,675
1,115,025
Cash flow
Cash from operating activities
(1,433,809)
(1,333,847)
(1,387,021)
CAPEX
(71,016)
(96,079)
(30,346)
Cash from investing activities
(83,571)
(97,352)
(24,682)
Cash from financing activities
1,079,542
(123,290)
1,597,317
FCF
(1,820,324)
(1,704,618)
(1,826,024)
Balance
Cash
380,752
786,233
2,222,977
Long term investments
201,480
203,564
180,050
Excess cash
579,161
988,677
2,402,757
Stockholders' equity
(11,415,311)
(8,849,507)
(7,438,931)
Invested Capital
13,978,432
12,090,692
11,992,752
ROIC
ROCE
EV
Common stock shares outstanding
130,129
121,145
111,845
Price
65.10
-38.13%
105.22
-39.59%
174.17
56.80%
Market cap
8,471,378
-33.54%
12,746,831
-34.56%
19,480,084
88.46%
EV
11,352,708
15,435,506
20,595,109
EBITDA
(1,775,917)
(1,323,958)
(1,355,602)
EV/EBITDA
Interest
57,384
54,720
46,222
Interest/NOPBT